Korro Bio Stock Gets Higher EPS Estimate from HC Wainwright

Korro Bio, Inc. (NASDAQ:KRRO – Free Report) – HC Wainwright upped their FY2026 earnings estimates for Korro Bio in a research note issued to investors on Friday, November 6th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($4.26) per share for the year, up from their previous forecast of ($4.88). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($4.45) per share. HC Wainwright also issued estimates for Korro Bio’s Q4 2026 earnings at ($0.73) EPS, Q3 2027 earnings at ($1.25) EPS and FY2027 earnings at ($5.03) EPS.

Korro Bio (NASDAQ:KRRO – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.16.

KRRO has been the topic of several other research reports. Wall Street Zen raised Korro Bio from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Jefferies Financial Group set a $15.00 target price on Korro Bio in a research report on Tuesday, October 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Korro Bio in a research note on Friday, October 2nd. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $16.50.

View Our Latest Stock Analysis on KRRO

Korro Bio Stock Down 8.4%

Shares of Korro Bio stock opened at $14.41 on Tuesday. Korro Bio has a 12 month low of $5.20 and a 12 month high of $33.92. The business has a fifty day simple moving average of $11.77 and a 200 day simple moving average of $12.13.

Insider Activity

In other Korro Bio news, major shareholder Lynx1 Capital Management Lp acquired 52,175 shares of the firm’s stock in a transaction that occurred on Thursday, October 22nd. The stock was acquired at an average cost of $10.72 per share, for a total transaction of $559,316.00. Following the transaction, the insider owned 1,597,155 shares of the company’s stock, valued at $17,121,501.60. This trade represents a 3.38% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jean Formela sold 28,468 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $14.00, for a total value of $398,552.00. Following the completion of the transaction, the director owned 141,053 shares of the company’s stock, valued at $1,974,742. This represents a 16.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have acquired 79,809 shares of company stock worth $884,919 and have sold 36,126 shares worth $502,148. 4.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. acquired a new position in shares of Korro Bio in the third quarter valued at approximately $54,000. North Star Investment Management Corp. increased its position in shares of Korro Bio by 1,044.4% during the third quarter. North Star Investment Management Corp. now owns 20,600 shares of the company’s stock worth $204,000 after acquiring an additional 18,800 shares in the last quarter. Deutsche Bank AG acquired a new stake in shares of Korro Bio during the second quarter worth $210,000. Hsbc Holdings PLC acquired a new stake in shares of Korro Bio during the second quarter worth $233,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Korro Bio by 15.2% during the first quarter. Bank of New York Mellon Corp now owns 21,730 shares of the company’s stock worth $246,000 after acquiring an additional 2,875 shares during the period. Institutional investors own 13.18% of the company’s stock.

Korro Bio Company Profile

(Get Free Report)

Korro Bio, Inc. is a clinical-stage biotechnology company developing RNA editing medicines for genetically driven diseases. The company’s approach is designed to make targeted changes to messenger RNA, potentially correcting or altering disease-related genetic instructions without permanently changing a patient’s DNA. Korro Bio’s technology platform uses programmable oligonucleotides to guide RNA editing in specific cells and tissues. Its lead development program, KRRO-110, is being developed for alpha-1 antitrypsin deficiency, an inherited disorder caused by mutations in the SERPINA1 gene that can lead to liver and lung disease.

Featured Articles

Earnings History and Estimates for Korro Bio (NASDAQ:KRRO)

Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.